Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models

One of the objectives of oncology phase I dose‐escalation studies has been to determine the maximum tolerated dose (MTD). Although MTD is no longer set as the dose for further development in contemporary oncology drug development, MTD determination is still important for informing the therapeutic in...

Descripción completa

Detalles Bibliográficos
Autores principales: Pantoja, Kristyn, Lanke, Shankar, Munafo, Alain, Victor, Anja, Habermehl, Christina, Schueler, Armin, Venkatakrishnan, Karthik, Girard, Pascal, Goteti, Kosalaram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574748/
https://www.ncbi.nlm.nih.gov/pubmed/35852048
http://dx.doi.org/10.1002/psp4.12851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574748/
https://www.ncbi.nlm.nih.gov/pubmed/35852048
http://dx.doi.org/10.1002/psp4.12851

Ejemplares similares